Shares of Israel-based
Pluristem Therapeutics, Inc
) reached a 52-week high of $3.81 during the course of the
trading session on Jan 2, 2013. Pluristem, however, closed the
trading session at $3.77.
The year-to-date return of 10.9% looks stable. Hence,
long-term investors can add Pluristem at current levels.
Pluristem currently Zacks Rank #2 (Buy). The company had a
market cap of $210.8 million as on Jan 2, 2013. The average
trading volume for the last three months was about 146,131
Pluristem develops and manufactures cell therapy products in
collaboration with companies like
) or through research and clinical institutions.
Pluristem intends to develop and produce cell therapy products
for the treatment of multiple disorders using several methods of
The cells from placenta are derived using the company's
proprietary PluriX therapy and are known as PLacental eXpanded
cells. Pluristem's first candidate in development, PLX-PAD, is
intended to treat peripheral artery disease (PAD).
Pluristem received a major relief in Sep 2013 when the U.S.
Food and Drug Administration (FDA) lifted the clinical hold on
its phase II intermittent claudication (IC) indication. IC is a
subset of peripheral artery disease (PAD).
We note that the clinical hold was lifted after Pluristem
addressed all issues raised by the FDA while placing the clinical
We remind investors that the FDA placed a clinical hold on the
company's phase II IC study in Jun 2013 following a serious
allergic reaction in one of the patients who required subsequent
hospitalization. The patient was discharged the next day after
the symptoms were managed.
Pluristem pointed out that the patient was suffering from
multiple diseases which might have affected the severity of the
Consequently, Pluristem provided the agency with additional
information to speed up the review and resolution of the issues.
We expect investor focus to remain on updates on PLX-PAD.
The stock is trading at a price to book ratio of 4.1x compared
to the peer group average of 4.07.
Other Stocks to Consider
Currently, companies like
Lannett Company, Inc.
) look well positioned with a Zacks Rank #1 (Strong Buy).
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
LANNETT INC (LCI): Free Stock Analysis Report
PLURISTEM THERA (PSTI): Free Stock Analysis
UTD THERAPEUTIC (UTHR): Free Stock Analysis
To read this article on Zacks.com click here.